{rfName}

Indexed in

License and use

Icono OpenAccess

Altmetrics

Grant support

This study was supported by the la Caixa Foundation (CLLEvolution- LCF/PR/HR17/52150017 [HR17-00221LCF] and CLLSYSTEMS-LCF/PR/HR22/52420015 [HR22-00172] Health Research 2017 and 2022 Programs, to EC), the Ministry of Science and Innovation (MCIN)/AEI/10.13039/501100011033 and the European Regional Development Fund (FEDER) Una manera de hacer Europa (PDC2022-133340-I00 and PID2021-123054OB-I00, to EC and PID2021-123165OB-I00 to DC), European Union NextGenerationEU/Mecanismo para la Recuperacion y la Resilencia (MRR)/PRTR and the Instituto de Salud Carlos III (ISCIII) (PMP21/00015 to EC), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2021-SGR-01172 to EC and 2021-SGR-01294 to DC), and the CERCA program from Generalitat de Catalunya. FN acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_ TATA_21_3223). EC is an Academia Researcher of the Institucio Catalana de Recerca i Estudis Avancats (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (CEK, Barcelona, Spain).

Analysis of institutional authors

Lopez-Oreja, IAuthorLopez-Guerra, MAuthorCorrea, JAuthorMozas, PAuthorRuiz-Gaspa, SAuthorBea, SAuthorJares, PAuthorCampo, EAuthorColomer, DCorresponding AuthorNadeu, FCorresponding Author

Share

Publications
>
Letters

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia

Publicated to:Hemasphere. 7 (10): e962- - 2023-10-01 7(10), DOI: 10.1097/hs9.0000000000000962

Authors: Lopez-Oreja, Irene; Lopez-Guerra, Monica; Correa, Juan; Mozas, Pablo; Muntanola, Ana; Munoz, Luz; Salgado, Ana-Camino; Ruiz-Gaspa, Silvia; Costa, Dolors; Bea, Silvia; Jares, Pedro; Campo, Elias; Colomer, Dolors; Nadeu, Ferran

Affiliations

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. - Author
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain - Author
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Seccio Hematopatol, Serv Anat Patol, Barcelona, Spain - Author
Hosp Clin Barcelona, Serv Hematol, Barcelona, Spain - Author
Hosp Gen Univ Vic, Serv Hematol, Barcelona, Spain - Author
Hosp Parc Tauli, Serv Hematol, Sabadell, Spain - Author
Hosp Univ Mutua Terrassa, Serv Hematol, Barcelona, Spain - Author
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain - Author
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. - Author
Servei d'Hematologia, Hospital Clinic de Barcelona, Spain. - Author
Univ Barcelona, Barcelona, Spain - Author
Universitat de Barcelona, Spain. - Author
See more

Abstract

[No abstract available]

Keywords

Amino acid sequenceArticleAtm proteinBaculoviral iap repeat containing protein 3Bruton tyrosine kinaseChemokine receptor cxcr4Chronic lymphatic leukemiaClinical impactClinical impact,mutations,tool,iCopy number variationDisease classificationEarly growth response factor 2Exportin 1F box/wd repeat containing protein 7Fluorescence in situ hybridizationGene mutationGene rearrangementGenomic dnaGold standardHigh throughput sequencingIgIndel mutationK ras proteinMutationsMyeloid differentiation factor 88Notch1 receptorProtein bcl 2Protein p53Sanger sequencingSingle nucleotide polymorphismSomatic hypermutationToolTurnaround timeValidation processWhole exome sequencingWhole genome sequencing

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Hemasphere due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 7/97, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.43, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-20, the following number of citations:

  • WoS: 3
  • Scopus: 3
  • Europe PMC: 2
  • OpenCitations: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-20:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 15.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 15 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 13.85.
  • The number of mentions on the social network X (formerly Twitter): 20 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (López Oreja, Irene) and Last Author (Nadeu Prat, Ferran).

the authors responsible for correspondence tasks have been Colomer Pujol, Dolors and Nadeu Prat, Ferran.